3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Multiple Myeloma
3
Leukemia, Myeloid, Acute
3
Recurrence
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myelomonocytic, Juvenile
2
Congenital Abnormalities
2
Waldenstrom Macroglobulinemia
1
Thrombocythemia, Essential
1
Sezary Syndrome
1
Sarcoma, Myeloid
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Neoplasms, Plasma Cell
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Mastocytosis
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Neutrophilic, Chronic
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Large Granular Lymphocytic
1
Interventions
Cyclophosphamide
12
fludarabine phosphate
7
fludarabine
7
venetoclax
6
blinatumomab
6
Cytarabine
5
Lenalidomide
4
Dexamethasone
4
Blood Specimen Collection
4
Azacitidine
4
obinutuzumab
3
Rituximab
3
Radiotherapy
3
Melphalan
3
Immunotherapy, Adoptive
3
pembrolizumab
2
daratumumab
2
Neoadjuvant Therapy
2
Idarubicin
2
Chemotherapy, Adjuvant
2
Capecitabine
2
trastuzumab deruxtecan
1
tislelizumab
1
tisagenlecleucel
1
thymoglobulin
1
tetrathiomolybdate
1
talquetamab
1
tagraxofusp
1
sacituzumab govitecan
1
sabatolimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
Transplantation
×
1 year
×
Clear all
NCT07443592
2026-03-02
LAL-2025
PETHEMA Foundation
Phase NA
Not yet recruiting
330 enrolled